Shares in Clinuvel Pharmaceuticals Ltd (ASX: CUV) climbed around 5% to $10.40 on Monday after the ASX biotech stock confirmed its shares will begin trading on the Nasdaq stock exchange in the US.

The Nasdaq is the world’s second-largest stock exchange after the New York Stock Exchange. It is home to many of the world’s leading technology and healthcare companies, including Nvidia Corp (NASDAQ: NVDA) and Microsoft Corp (NASDAQ: MSFT).

Clinuvel confirms Nasdaq debut

In an ASX announcement today, the ASX biotech stock said its American Depositary Shares (ADS) are expected to commence trading on the Nasdaq later on Monday (New York time) under the ticker CUVL.

The milestone follows the US Securities and Exchange Commission declaring the company’s Form 20-F registration statement effective on 17 July, along with Nasdaq approving the listing.

As part of the move, Clinuvel’s existing over-the-counter American Depositary Receipt (ADR) program will be upgraded from a Level I ADR to a Level II ADS listed on Nasdaq. Each ADS will represent one ordinary Clinuvel share listed on the ASX.

Importantly, the company is not raising capital or issuing new shares as part of the listing. This means the move is designed to improve market access rather than fund the business.

Existing holders of Clinuvel’s US-traded ADRs also won’t need to take any action. Their holdings will automatically transition to the new Nasdaq-listed security.

Why does a Nasdaq listing matter?

A Nasdaq listing can significantly increase a company’s visibility among US investors and improve trading liquidity. It also provides access to specialist healthcare and biotechnology investors who are often more familiar with the sector and can broaden the company’s shareholder base.

The Nasdaq Global Select Market, where the ASX biotech stock will trade, also offers greater analytical coverage and inclusion in Nasdaq’s market ecosystem. This potentially increases awareness among institutional investors.

That said, investors shouldn’t expect the listing alone to transform the company’s fortunes overnight. Greater visibility could support future growth opportunities and provide access to deeper capital markets if required. However, Clinuvel’s long-term success will ultimately depend on executing its commercial strategy.

What did management say?

Clinuvel Chairman Jeffrey Rosenfeld said:

The upgrade of CUVL to the Nasdaq marks an important step for Clinuvel’s visibility in U.S. capital markets, as well as reflecting a broader shift of our business towards North America. In the context of all our activities, the gradual shift to the U.S. makes much sense as the Company is maturing.

Foolish Takeaway

Clinuvel already has a commercialised product in SCENESSE®. It is approved in multiple markets, including the United States and Europe.

The Nasdaq listing has the potential to raise the international profile of the ASX biotech stock. It also expands its access to one of the world’s deepest pools of healthcare capital.

However, the real driver of long-term shareholder returns will remain business execution.

Despite today’s rally, Clinuvel shares are still down around 17% so far this year. This suggests investors are waiting for stronger evidence that the company’s next phase of growth is taking shape.

The post This ASX biotech stock just scored a Nasdaq listing. Shares are jumping appeared first on The Motley Fool Australia.

More reading

• This ASX biotech stock is tipped to double or even triple in value

Motley Fool contributor Marc Van Dinther has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Microsoft and Nvidia. The Motley Fool Australia has recommended Microsoft and Nvidia. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Pro Medicus Ltd (ASX: PME) shares are pushing higher today.

Shares in the S&P/ASX 200 Index (ASX: XJO) health imaging company closed on Friday trading for $187.11. As we head into the Monday lunch hour, shares are swapping hands for $188.83 each, up 0.9%.

For some context, the ASX 200 is up 0.2% at this same time.

With today’s intraday lift factored in, Pro Medicus shares are now up an impressive 74.6% since notching a one-year closing low of $108.15 on 24 February.

That strong rebound followed months of heavy selling after the stock hit an all-time closing high of $330.48 a share on 17 July 2025.

As you may be aware, that selling pressure came amid a broader global sell-down of Software as a Service (SaaS) stocks.

The so-called SaaSpocalypse hit Pro Medicus and many other stocks dependent on their proprietary software amid concerns that artificial intelligence might replace the services these companies provide.

But with those concerns clearly fading for Pro Medicus over the past five months, is the ASX 200 healthcare share still a good buy today?

Should I buy Pro Medicus shares now?

Alto Capital’s Tony Locantro recently ran his slide rule over the ASX 200 stock (courtesy of The Bull).

“The company provides medical imaging software and services to hospitals and healthcare groups across the world,” he said.

Locantro noted:

The company recently delivered an outstanding first half result in full year 2026. Underlying earnings before interest and tax was up 29.7% and revenue was up 28.4% amid securing more than A$280 million in new contract wins.

But following the strong rebound in Pro Medicus shares since February, Locantro issued a sell recommendation on the stock.

He concluded:

Despite these exceptional fundamentals, the company’s premium valuation reflects high market expectations and leaves limited room for disappointment. While Pro Medicus remains a best-in-class business with strong long-term prospects, the current risk-reward balance supports a view to trim holdings at current levels.

What else did the ASX 200 healthcare share report for H1 FY 2026?

Atop the strong earnings and revenue growth Locantro mentioned above, Pro Medicus shares have also been grabbing investor attention amid surging profits.

The company reported first-half net profit after tax of $171.2 million, up 230.9% year on year.

“Our profits continue to grow strongly even though our biggest implementation during the period in Trinity Cohort 1 went live towards the end of October so had limited impact on the half,” Pro Medicus CEO Sam Hupert said on the day of the results release.

The post Up 75%, are Pro Medicus shares still a good buy now? appeared first on The Motley Fool Australia.

More reading

• Why WiseTech shares could rocket 100%
• Where to invest $10,000 in ASX 200 shares in July
• Buy, hold, sell: Pro Medicus, Worley, and ResMed shares
• Buy, hold, sell: TechnologyOne, Pro Medicus, PLS Group shares
• 9 ASX 200 shares with reiterated buy calls this week

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has recommended Pro Medicus. The Motley Fool Australia has recommended Pro Medicus. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Despite turbulent world events, including the war in the Middle East, Australian superannuation funds have chalked up a fourth straight year of strong returns, with UniSuper Growth edging out its peers to be the best performer over the period.

Excellent superannuation returns once again

Data released by Chant West indicates that the median growth superannuation fund, which is 61% to 80% invested in growth assets, gained a healthy 9.5% during FY26.

Chant West said this followed returns of 9.2% in FY23, 9.1% in FY24, and 10.4% in FY25, “taking the cumulative return to an impressive 44% over the past four years”.

Members invested in higher-risk options would generally have enjoyed even better outcomes, the analytics company said.

Chant West Head of Super Investment Mano Mohankumar said the FY26 result was once again driven by international shares, but it also helped that nearly all asset classes generated positive returns over the period.

He added:

International shares surged 25.5% in hedged terms, supported by continued enthusiasm for AI and robust corporate earnings. Despite the Australian dollar’s appreciation against most major currencies, the return in unhedged terms delivered an impressive 17%. International shares have the highest allocation within a typical growth fund, accounting for about 31% on average. By comparison, Australian shares, which on average has a weighting of 24%, returned a modest 6.2% over the year.

Mr Mohankumar said generally speaking, funds with a higher allocation to international shares performed better.

He added:

Diversification also provided some benefit given the wide dispersion of returns across asset classes, though it would have helped if you had lower allocations to traditional defensive assets. Australian bonds, international bonds and cash returned 1.5%, 2.9% and 3.9%, respectively, making them among the weakest performing asset classes over the year. The only asset class to finish in negative territory was Australian listed property, which declined 1.8%. In contrast, international listed real assets performed exceptionally well, with international listed infrastructure and listed property returning 17.2% and 14.3%, respectively.

Which were the best-performing superannuation funds?

Among growth funds, the top-performing growth funds for the year were UniSuper Growth with 12.3%, NGS Super Diversified with 11.5%, CFS Firstchoice Growth with 11.5%, and Hostplus Balanced with 10.8%.

Mr Mohankumar said that while super funds had delivered four straight years of returns of 9% or more, that level of return shouldn’t be thought of as normal.

He added:

The typical long-term return objective for growth funds is to beat inflation by 3.5% p.a., which translates to roughly 6% p.a. Since the introduction of compulsory super, the annualised return is 8% and the annual CPI increase is 2.7%, giving a real return of 5.3% p.a. – well above that 3.5% target. Even looking at the past 20 years, which includes three major share market downturns – the GFC in 2007-2009, COVID-19 in 2020 and the high inflation and rising interest rates in 2022 – super funds have returned 6.9% p.a., which is still comfortably ahead of the typical objective.

The post Which superannuation fund outperformed its peers last financial year? appeared first on The Motley Fool Australia.

More reading

• This ASX biotech stock just scored a Nasdaq listing. Shares are jumping
• Up 75%, are Pro Medicus shares still a good buy now?
• Why South32 shares edge higher on strong results and landmark deal
• Average superannuation balance for 56 vs 66-year-olds in 2026. How does yours compare?
• Billionaire Andrew Forrest’s buy up sends ASX mining share soaring

Motley Fool contributor Cameron England has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.